Skip to main content
Top
Published in: BMC Pediatrics 1/2015

Open Access 01-12-2015 | Research article

Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics

Authors: Tomoko Horinouchi, Kandai Nozu, Kiyoshi Hamahira, Yosuke Inaguma, Jun Abe, Hiroshi Nakajima, Masaaki Kugo, Kazumoto Iijima

Published in: BMC Pediatrics | Issue 1/2015

Login to get access

Abstract

Background

The etiology of Kawasaki disease (KD) is unknown. Reportedly, there is an association between KD and Yersinia pseudotuberculosis (YPT). Steroid therapy for KD patients with high risk of cardiac sequelae (CS) has been reported; however, the number of reports is limited.

Methods

We conducted a prospective study of 108 patients with newly diagnosed KD in one year to determine how many KD patients have positive anti-YPT antibody titers and/or positive anti-YPT-derived mitogen (YPM) antibody titers. In addition, we tried to identify clinical differences between KD patients in whom YPT infection was or not a contributing factor. We also compared clinical characteristics of patients treated with the protocol of the Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease (RAISE) study (RAISE group) and with the conventional Intravenous immunoglobulin (IVIG) protocol (conventional group).

Results

Eleven patients (10 %) were positive for anti-YPT and/or anti-YPM antibodies (positive group) and 97 (90 %) were negative (negative group). Cardiac sequelae (CS) occurred significantly more frequently in the positive than the negative group (two patients, 18 % vs one patient, 1 %, p = 0.027). Forty patients were in the RAISE group. Two of 40 (5 %) in the RAISE group and one of 68 (1.47 %) in the conventional group had CS (p = 0.55).

Conclusions

KD patients with YPT infection had CS significantly more frequently and treatment with RAISE protocol did not decrease the frequency of CS in our cohort, nor did YPT infection affect risk scores of no response to IVIG. However, our sample size was overly small to draw such conclusions. Further investigation in a larger cohort is necessary to confirm our findings. Additionally, further research is needed to determine whether early diagnosis of YPT can prevent KD from developing and reduce the incidence of CS.
Literature
1.
go back to reference Saundankar J, Yim D, Itotoh B, Payne R, Maslin K, Jape G, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics. 2014;133:e1009–14.CrossRefPubMed Saundankar J, Yim D, Itotoh B, Payne R, Maslin K, Jape G, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics. 2014;133:e1009–14.CrossRefPubMed
2.
go back to reference Huang SK, Lin MT, Chen HC, Huang SC, Wu MH. Epidemiology of Kawasaki disease: prevalence from national database and future trends projection by system dynamics modeling. J Pediatr. 2013;163:126–31. e121.CrossRefPubMed Huang SK, Lin MT, Chen HC, Huang SC, Wu MH. Epidemiology of Kawasaki disease: prevalence from national database and future trends projection by system dynamics modeling. J Pediatr. 2013;163:126–31. e121.CrossRefPubMed
4.
go back to reference Konishi N, Baba K, Abe J, Maruko T, Waki K, Takeda N, et al. A case of Kawasaki disease with coronary artery aneurysms documenting Yersinia pseudotuberculosis infection. Acta Paediatr. 1997;86:661–4.CrossRefPubMed Konishi N, Baba K, Abe J, Maruko T, Waki K, Takeda N, et al. A case of Kawasaki disease with coronary artery aneurysms documenting Yersinia pseudotuberculosis infection. Acta Paediatr. 1997;86:661–4.CrossRefPubMed
5.
go back to reference Baba K, Takeda N, Tanaka M. Cases of Yersinia pseudotuberculosis infection having diagnostic criteria of Kawasaki disease. Contrib Microbiol Immunol. 1991;12:292–6.PubMed Baba K, Takeda N, Tanaka M. Cases of Yersinia pseudotuberculosis infection having diagnostic criteria of Kawasaki disease. Contrib Microbiol Immunol. 1991;12:292–6.PubMed
6.
go back to reference Sato K, Ouchi K, Komazawa M. Ampicillin vs. placebo for Yersinia pseudotuberculosis infection in children. Pediatr Infect Dis J. 1988;7:686–9.CrossRefPubMed Sato K, Ouchi K, Komazawa M. Ampicillin vs. placebo for Yersinia pseudotuberculosis infection in children. Pediatr Infect Dis J. 1988;7:686–9.CrossRefPubMed
7.
go back to reference Tahara M, Baba K, Waki K, Arakaki Y. Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis. Acta Paediatr. 2006;95:1661–4.CrossRefPubMed Tahara M, Baba K, Waki K, Arakaki Y. Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis. Acta Paediatr. 2006;95:1661–4.CrossRefPubMed
8.
go back to reference Bogdanovich T, Carniel E, Fukushima H, Skurnik M. Use of O-antigen gene cluster-specific PCRs for the identification and O-genotyping of Yersinia pseudotuberculosis and Yersinia pestis. J Clin Microbiol. 2003;41:5103–12.CrossRefPubMedPubMedCentral Bogdanovich T, Carniel E, Fukushima H, Skurnik M. Use of O-antigen gene cluster-specific PCRs for the identification and O-genotyping of Yersinia pseudotuberculosis and Yersinia pestis. J Clin Microbiol. 2003;41:5103–12.CrossRefPubMedPubMedCentral
9.
go back to reference Bogdanovich TM, Carniel E, Fukushima H, Skurnik M. Genetic (sero) typing of Yersinia pseudotuberculosis. Adv Exp Med Biol. 2003;529:337–40.CrossRefPubMed Bogdanovich TM, Carniel E, Fukushima H, Skurnik M. Genetic (sero) typing of Yersinia pseudotuberculosis. Adv Exp Med Biol. 2003;529:337–40.CrossRefPubMed
10.
go back to reference Hayashidani HT I. Yersinia pseudotuberculosis infection. Modern media (in Japanese). Modern Media. 2005;51:211–6. Hayashidani HT I. Yersinia pseudotuberculosis infection. Modern media (in Japanese). Modern Media. 2005;51:211–6.
11.
go back to reference Carniel E. The Yersinia high-pathogenicity island. Int Microbiol. 1999;2:161–7.PubMed Carniel E. The Yersinia high-pathogenicity island. Int Microbiol. 1999;2:161–7.PubMed
12.
go back to reference Carnoy C, Mullet C, Muller-Alouf H, Leteurtre E, Simonet M. Superantigen YPMa exacerbates the virulence of Yersinia pseudotuberculosis in mice. Infect Immun. 2000;68:2553–9.CrossRefPubMedPubMedCentral Carnoy C, Mullet C, Muller-Alouf H, Leteurtre E, Simonet M. Superantigen YPMa exacerbates the virulence of Yersinia pseudotuberculosis in mice. Infect Immun. 2000;68:2553–9.CrossRefPubMedPubMedCentral
13.
go back to reference Cornelis GR, Biot T, Lambert de Rouvroit C, Michiels T, Mulder B, Sluiters C, et al. The Yersinia yop regulon. Mol Microbiol. 1989;3:1455–9.CrossRefPubMed Cornelis GR, Biot T, Lambert de Rouvroit C, Michiels T, Mulder B, Sluiters C, et al. The Yersinia yop regulon. Mol Microbiol. 1989;3:1455–9.CrossRefPubMed
14.
go back to reference Abe J, Onimaru M, Matsumoto S, Noma S, Baba K, Ito Y, et al. Clinical role for a superantigen in Yersinia pseudotuberculosis infection. J Clin Invest. 1997;99:1823–30.CrossRefPubMedPubMedCentral Abe J, Onimaru M, Matsumoto S, Noma S, Baba K, Ito Y, et al. Clinical role for a superantigen in Yersinia pseudotuberculosis infection. J Clin Invest. 1997;99:1823–30.CrossRefPubMedPubMedCentral
15.
go back to reference Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613–20.CrossRefPubMed Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613–20.CrossRefPubMed
16.
go back to reference Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47:232–4.CrossRefPubMed Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47:232–4.CrossRefPubMed
17.
go back to reference Paff JR, Triplett DA, Saari TN. Clinical and laboratory aspects of Yersinia pseudotuberculosis infections, with a report of two cases. Am J Clin Pathol. 1976;66:101–10.CrossRefPubMed Paff JR, Triplett DA, Saari TN. Clinical and laboratory aspects of Yersinia pseudotuberculosis infections, with a report of two cases. Am J Clin Pathol. 1976;66:101–10.CrossRefPubMed
18.
go back to reference Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014;56:135–58.CrossRef Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014;56:135–58.CrossRef
19.
go back to reference Group JCSJW. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J. 2014;78:2521–62.CrossRef Group JCSJW. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J. 2014;78:2521–62.CrossRef
20.
go back to reference Sato K, Ouchi K, Taki M. Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome. Pediatr Infect Dis. 1983;2:123–6.CrossRefPubMed Sato K, Ouchi K, Taki M. Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome. Pediatr Infect Dis. 1983;2:123–6.CrossRefPubMed
21.
go back to reference Fukushima H, Matsuda Y, Seki R, Tsubokura M, Takeda N, Shubin FN, et al. Geographical heterogeneity between Far Eastern and Western countries in prevalence of the virulence plasmid, the superantigen Yersinia pseudotuberculosis-derived mitogen, and the high-pathogenicity island among Yersinia pseudotuberculosis strains. J Clin Microbiol. 2001;39:3541–7.CrossRefPubMedPubMedCentral Fukushima H, Matsuda Y, Seki R, Tsubokura M, Takeda N, Shubin FN, et al. Geographical heterogeneity between Far Eastern and Western countries in prevalence of the virulence plasmid, the superantigen Yersinia pseudotuberculosis-derived mitogen, and the high-pathogenicity island among Yersinia pseudotuberculosis strains. J Clin Microbiol. 2001;39:3541–7.CrossRefPubMedPubMedCentral
22.
go back to reference Yoshino K, Ramamurthy T, Nair GB, Fukushima H, Ohtomo Y, Takeda N, et al. Geographical heterogeneity between Far East and Europe in prevalence of ypm gene encoding the novel superantigen among Yersinia pseudotuberculosis strains. J Clin Microbiol. 1995;33:3356–8.PubMedPubMedCentral Yoshino K, Ramamurthy T, Nair GB, Fukushima H, Ohtomo Y, Takeda N, et al. Geographical heterogeneity between Far East and Europe in prevalence of ypm gene encoding the novel superantigen among Yersinia pseudotuberculosis strains. J Clin Microbiol. 1995;33:3356–8.PubMedPubMedCentral
23.
go back to reference Abe J, Takeda T, Watanabe Y, Nakao H, Kobayashi N, Leung DY, et al. Evidence for superantigen production by Yersinia pseudotuberculosis. J Immunol. 1993;151:4183–8.PubMed Abe J, Takeda T, Watanabe Y, Nakao H, Kobayashi N, Leung DY, et al. Evidence for superantigen production by Yersinia pseudotuberculosis. J Immunol. 1993;151:4183–8.PubMed
24.
go back to reference Uchiyama T, Miyoshi-Akiyama T, Kato H, Fujimaki W, Imanishi K, Yan XJ. Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute and systemic symptoms. J Immunol. 1993;151:4407–13.PubMed Uchiyama T, Miyoshi-Akiyama T, Kato H, Fujimaki W, Imanishi K, Yan XJ. Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute and systemic symptoms. J Immunol. 1993;151:4407–13.PubMed
25.
go back to reference Kusuda T, Nakashima Y, Murata K, Kanno S, Nishio H, Saito M, et al. Kawasaki disease-specific molecules in the sera are linked to microbe-associated molecular patterns in the biofilms. PLoS One. 2014;9, e113054.CrossRefPubMedPubMedCentral Kusuda T, Nakashima Y, Murata K, Kanno S, Nishio H, Saito M, et al. Kawasaki disease-specific molecules in the sera are linked to microbe-associated molecular patterns in the biofilms. PLoS One. 2014;9, e113054.CrossRefPubMedPubMedCentral
26.
go back to reference Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662–7.CrossRefPubMed Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662–7.CrossRefPubMed
27.
go back to reference Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129:e17–23.CrossRefPubMed Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129:e17–23.CrossRefPubMed
28.
go back to reference Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161:506–12. e501.CrossRefPubMedPubMedCentral Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161:506–12. e501.CrossRefPubMedPubMedCentral
29.
go back to reference Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146–9.CrossRefPubMed Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146–9.CrossRefPubMed
30.
go back to reference Lemaitre BC, Mazigh DA, Scavizzi MR. Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection. Antimicrob Agents Chemother. 1991;35:1785–90.CrossRefPubMedPubMedCentral Lemaitre BC, Mazigh DA, Scavizzi MR. Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection. Antimicrob Agents Chemother. 1991;35:1785–90.CrossRefPubMedPubMedCentral
31.
go back to reference Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord. 2005;5:11.CrossRefPubMedPubMedCentral Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord. 2005;5:11.CrossRefPubMedPubMedCentral
32.
go back to reference Horisaka T, Fujita K, Iwata T, Nakadai A, Okatani AT, Horikita T, et al. Sensitive and specific detection of Yersinia pseudotuberculosis by loop-mediated isothermal amplification. J Clin Microbiol. 2004;42:5349–52.CrossRefPubMedPubMedCentral Horisaka T, Fujita K, Iwata T, Nakadai A, Okatani AT, Horikita T, et al. Sensitive and specific detection of Yersinia pseudotuberculosis by loop-mediated isothermal amplification. J Clin Microbiol. 2004;42:5349–52.CrossRefPubMedPubMedCentral
33.
go back to reference Etoom Y, Banihani R, Finkelstein Y. Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. J Popul Ther Clin Pharmacol. 2013;20:e91–4.PubMed Etoom Y, Banihani R, Finkelstein Y. Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. J Popul Ther Clin Pharmacol. 2013;20:e91–4.PubMed
34.
go back to reference Yim D, Curtis N, Cheung M, Burgner D. An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes. J Paediatr Child Health. 2013;49:614–23.CrossRefPubMed Yim D, Curtis N, Cheung M, Burgner D. An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes. J Paediatr Child Health. 2013;49:614–23.CrossRefPubMed
Metadata
Title
Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics
Authors
Tomoko Horinouchi
Kandai Nozu
Kiyoshi Hamahira
Yosuke Inaguma
Jun Abe
Hiroshi Nakajima
Masaaki Kugo
Kazumoto Iijima
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2015
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-015-0497-2

Other articles of this Issue 1/2015

BMC Pediatrics 1/2015 Go to the issue